Market revenue in 2020 | USD 173.4 million |
Market revenue in 2028 | USD 214.6 million |
Growth rate | 2.7% (CAGR from 2020 to 2028) |
Largest segment | Reagents |
Fastest growing segment | Reagents |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Reagents |
Key market players worldwide | Abbott Laboratories, Danaher Corp, BioMerieux SA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Becton Dickinson & Co, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to infectious disease molecular diagnostics market will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 67.07% in 2020. Horizon Databook has segmented the Mexico infectious disease molecular diagnostics market based on instruments, reagents covering the revenue growth of each sub-segment from 2018 to 2028.
Mexico is a prominent market for infectious diseases molecular diagnostics in Latin America. Due to the large population, controlling the incidence of infectious diseases is a major challenge in Mexico. Healthcare institutions have undertaken initiatives to spread awareness about early diagnosis of infectious diseases through healthcare camps.
Favorable government regulations pertaining to approval of molecular diagnostics are expected to boost market growth. In Mexico, COFEPRIS—division of the Mexican Ministry of Health—governs the approval process for IVDs and molecular diagnostics.
The organization announced these plans in early 2017. For instance, in July 2020, COFEPRIS approved DiaCarta’s QuantiVirus SARS-CoV-2 test for marketing in Mexico, which is a PCRbased test. The test has been evaluated and approved by the Ministry of Health through the Institute of Diagnostic and Epidemiological Reference (InDRE), in compliance with the guidelines established by WHO.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico infectious disease molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Mexico infectious disease molecular diagnostics market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account